Turning Scientific Discovery into a Commercial Success with Kurome Therapeutics
Nearly two decades of research at Cincinnati Children’s has resulted in successful development of KME-0584, a small-molecule drug now set to open clinical trials. This groundbreaking therapy, licensed to Kurome Therapeutics, aims to treat refractory/relapsed AML and high-risk MDS, both of which have limited treatment options.
The drug, based on research led by Daniel Starczynowski, PhD, associate director of the Cancer and Blood Diseases Institute, targets IRAK1/4 signaling pathways critical to these diseases.
Kurome Therapeutics, founded with support from CincyTech, has synthesized over 1,600 derivatives of the initial compound, culminating in the FDA opening KME-0584's Investigational New Drug (IND) application to begin clinical trials. This milestone, supported by a $15 million Series A funding round, demonstrates Cincinnati Children's ability to take scientific innovation from concept to commercialization, offering new hope for patients while driving biotech success.
Visit our science blog to learn more about this research.
